Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...
Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...
Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...
Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.
Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. The ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...
Symptoms of NAION can include blurred vision, peripheral vision loss, dark spots in vision, and changes in color perception. Though the exact mechanism is not fully understood, researchers hypothesize ...
Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, ...
Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results